1		06 September 2023 Statement by proposed Directors Dear ImpediMed Shareholder, We are the proposed Directors named in the Notice of Meeting to be held on 28th September 2023 nominated to be appointed by you as Directors of your Company. We agreed to be nominated as Directors of ImpediMed because we consider the prospects for the Company to be significant in revolutionising patient care and delivering shareholder value. We believe our combined technical abilities, commercial skills and deep experiences will be strongly beneficial to enabling ImpediMed to realise its value potential. Collectively, we are highly experienced in creating, refining and executing strategy across blue-chip, technically oriented Australian and multinational organisations. Our ambition is to bring our skills to capitalise on the long-term potential of ImpediMed and ensure strong governance at board level so shareholders can be confident in the direction and strategy of the Company and maintain accountability of management. We are committed to preserving and enhancing the strong Australian DNA of the original technology in the same way that Resmed, Nanosonics, Pro Medicus, Polynovo and Cochlear have managed whilst addressing the significant market opportunity in North America and the rest of the world. We understand the need to show discipline and returns to shareholders as stewards of their capital. We are independent of the requisitioning shareholder group and have no past commercial associations with them. Our independence is critical to our ability to discharge our duties in the best interests of the Company and clearly it is important to our fellow shareholders. It is misleading to suggest we are not independent. The role of a Board is to work with management to define and shape strategy. Accordingly, it would not be appropriate for us to propose any significant changes in strategy without first consulting extensively with management. We note the Requisitioning Shareholders have raised their concerns around the Company’s strategy and these are detailed in a separate letter to shareholders prepared by the Requisitioning Shareholders. If we are appointed, we would take into consideration the concerns of all shareholders as part of our broader strategy discussions with management. Below is a summary of the relevant experience each of us would bring to ImpediMed. This includes extensive technical and commercial expertise in the medical device sector operating in all major global markets, development and execution of strategy, IT/delivery of digital solutions, IP, governance and finance. Further detailed biographical information is also attached to this statement. McGregor Grant Commercial and financial experience in growing Nanosonics, a successful ASX med-tech business, seeing revenues grow from m to 6m (90% revenue in North America) with a market capitalisation of .4b. Extensive global experience in the life sciences sector. Board administration, governance and investor relations experience. Janelle Delaney Three decades of project management and execution at IBM, withresponsibility for the quality of delivery across Asia Pacific’s portfolio of several thousand projects. Extensive knowledge and expertise in the delivery management of IT solutions including digital transformation, AI, big data, Cloud implementations and migrations, Cybersecurity, Package implementations, application management services and business process services. Andrew Grant Deep understanding and experience working with key US customers and across global healthcare markets, recently working with Cleveland Clinic on the technology transfer of oncology and cardiology service lines. Customer centric marketing and business development experience at ResMed in roles encompassing VP Global Product Marketing and VP Corporate Development. 20 years strategic planning experience and delivery in healthcare working with leading healthcare organisations globally and as a consultant with McKinsey & Co. Christine Emmanuel-Donnelly Healthcare governance experience as a Non-Executive Director of PolyNovo Ltd and Medical Developments International Ltd. In addition, non-ASX listed Pikcha Holdings Pty Ltd (trading as Seminal) US commercialization of NovoSorb (PolyNovo) providing exposure and insights to rapid growth of a medical device company based on an innovative technology platform with first mover advantage and an extensive IP portfolio. Over the past three years employee numbers and revenue have tripled. IP expertise through commercialisation and strategic in-house intellectual property roles at CSIRO and RMIT University, previously practising as a patent and trademarks attorney in leading AU and UK firms and Unilever (UK). We believe we would bring diversity to ImpediMed’s Board as well as deep relevant experience to support management effectively refine and execute on its strategic agenda. Importantly, we are highly cognisant of the need to minimise any disruption to the business so that management can focus on unlocking and maximising ImpediMed’s potential value. We acknowledge an invitation to meet with the ImpediMed Board. However, in the circumstances we do not consider it appropriate to engage directly with the current Board. We acknowledge that you are being asked to make a significant decision. If we are elected as directors of your Company, we assure you that we will serve the interests of all shareholders through strong governance and a focussed approach to ensure the development and effective implementation of strategy to realise the Company’s value potential. Yours sincerely, McGregor Grant Janelle Delaney Andrew Grant Christine Emmanuel-Donnelly Detailed biographical informationon proposed Directors Please click on the names below to see more information: McGregor Grant Janelle Delaney Andrew Grant Christine Emmanuel-Donnelly
2
3	To opt-out of receiving these communications, reply with the word "unsubscribe".

So ... this is the start .. more to come from Acadia re reasons etc etc shortly .. I would offer people really read this and the succinct points they make here.. look at their bio's .. and then link tis with what Acadia puts out re the reaons etc ..

staying tuned but the info is coming .

cheers all ..

Doggy ..